Full video transcriptClick to expand
Auto-generated transcript of @tanyalivingston13's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Alright guys, the rebellious, I told you I'd give you an update. Three days, three days in.
- 0:08And yep, it put me in the hospital. Same as the majourno. So my situation is with lupus. I guess
- 0:17it's just not beneficial for me. I have a lot of gastrointestinal issues so it's just not going to
- 0:22be the right thing for me. So I'm going to be doing it the whole natural with high protein,
- 0:27high fiber, trying to do it the natural way and lose weight. But I do wish a good luck. I
- 0:34start throwing up a green bile for over 24 hours and I was having cold sweats the whole time. I was
- 0:44soaking wet but I was freezing and then my lupus rush came out. So yep, that's me today. I'm in
- 0:50the hospital so I will not be doing the rebellious anymore or any GLP one. So I'm just going to try to
- 0:58do it the natural way.
Rybelsus and GI side effects: what 3 days actually tells you
Quick answer
The creator describes bilious vomiting lasting more than 24 hours, diaphoresis, and a lupus flare after three days of oral semaglutide (Rybelsus), with a reported similar reaction to tirzepatide (Mounjaro) previously. Her stated history of gastroparesis and gastritis represents a clinically recognized contraindication to GLP-1 receptor agonist therapy, as these medications further delay gastric emptying. The lupus flare is most plausibly explained by dehydration and physiological stress from protracted vomiting rather than a direct pharmacological interaction with semaglutide.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Rybelsus and GI side effects: what 3 days actually tells you, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Rybelsus and GI side effects: what 3 days actually tells you is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Rybelsus and GI side effects: what 3 days actually tells you" from Tanya Livingston. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes bilious vomiting lasting more than 24 hours, diaphoresis, and a lupus flare after three days of oral semaglutide (Rybelsus), with a reported similar reaction to tirzepatide (Mounjaro) previously.
The reason this review is not generic is the source wording and the canonical claim label "glp1 rybelsus after 3 day gastritis and gastropresis." In this clip, the useful excerpt is: "Alright guys, the rebellious, I told you I'd give you an update." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator describes bilious vomiting lasting more than 24 hours, diaphoresis, and a lupus flare after three days of oral semaglutide (Rybelsus), with a reported similar reaction to tirzepatide (Mounjaro) previously.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes bilious vomiting lasting more than 24 hours, diaphoresis, and a lupus flare after three days of oral semaglutide (Rybelsus), with a reported similar reaction to tirzepatide (Mounjaro) previously. Her stated history of gastroparesis and gastritis represents a clinically recognized contraindication to GLP-1 receptor agonist therapy, as these medications further delay gastric emptying. The lupus flare is most plausibly explained by dehydration and physiological stress from protracted vomiting rather than a direct pharmacological interaction with semaglutide.
- Pre-existing gastroparesis is a clinically recognized risk factor before starting GLP-1 therapy. The 2023 AGA clinical alert specifically flagged this population as requiring careful evaluation.
- Bilious vomiting lasting over 24 hours is not typical GLP-1 nausea. It is a symptom that warrants emergency care and is consistent with a gastroparesis exacerbation, not a standard side effect.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Pre-existing gastroparesis is a clinically recognized risk factor before starting GLP-1 therapy. The 2023 AGA clinical alert specifically flagged this population as requiring careful evaluation.
- Bilious vomiting lasting over 24 hours is not typical GLP-1 nausea. It is a symptom that warrants emergency care and is consistent with a gastroparesis exacerbation, not a standard side effect.
- In the PIONEER 1 trial (Aroda et al., 2019, Diabetes Care), nausea and vomiting with oral semaglutide occurred in about 15-20% of patients, but severe hospitalization-level events were rare and not representative of typical patient experience.
- Semaglutide does not have a documented direct mechanism for triggering lupus flares. Dehydration from any cause, including severe vomiting, is a known precipitant of autoimmune disease activity.
- Tanya's experience is a legitimate signal about prescreening failures, not evidence that GLP-1 medications are broadly dangerous for all patients.
- Patients with autoimmune conditions taking any new medication should establish a monitoring plan with their prescriber before starting, including clear criteria for when to seek emergency care.
- Both Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) delay gastric emptying through overlapping mechanisms. Reacting poorly to one does not automatically predict reaction to the other, but in a patient with severe gastroparesis, the risk is real for the entire drug class.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @tanyalivingston13 actually say?
Tanya said that after three days on Rybelsus (oral semaglutide), she ended up hospitalized with vomiting of green bile lasting over 24 hours, cold sweats, and a lupus flare. She also said the same thing happened with "the majourno" (almost certainly Mounjaro, tirzepatide). Her conclusion: GLP-1 medications are "just not going to be the right thing" for her given her gastrointestinal issues and lupus.
To be fair to her, she is not claiming this happens to everyone. She is sharing her own experience and explicitly wishes others good luck with GLP-1s. That framing matters. But 42,000 people watched this, and the takeaway many will absorb is that GLP-1 medications cause hospitalization. That deserves a closer look.
Does the science back this up?
GLP-1 receptor agonists do slow gastric emptying. That is not a side effect, it is part of how they work. For most people this causes nausea and occasional vomiting that fades over weeks. For someone who already has gastroparesis, this can get genuinely dangerous.
Tanya mentions she has "a lot of gastrointestinal issues," and she references both gastroparesis and gastritis in the video caption. The American Gastroenterological Association issued a clinical alert in 2023 flagging that GLP-1 agonists can significantly worsen gastroparesis symptoms in patients who already have delayed gastric emptying. Bharucha et al. (2022, Gastroenterology) documented cases where semaglutide precipitated severe gastroparesis exacerbations requiring hospitalization. Vomiting of bile (bilious emesis) over 24 hours is consistent with a severe gastroparesis episode, not just typical GLP-1 nausea. That is a meaningful clinical distinction.
The lupus connection is less clear-cut. There is no strong published evidence that semaglutide directly triggers lupus flares. Severe physiological stress, like protracted vomiting and dehydration, can precipitate autoimmune flares. That is a more plausible mechanistic explanation than a direct drug-lupus interaction.
What did they get wrong (or right)?
She got the core personal experience right: pre-existing gastroparesis is a genuine contraindication for GLP-1 therapy, and her hospitalization is clinically plausible given that history. That is not an overreaction or misinformation. That is a real risk that prescribers are supposed to screen for.
Where it gets murkier is the implied causation with lupus. Saying the medication "put" her in the hospital and triggered her lupus rash conflates two things. The vomiting causing dehydration and physiological stress, which then worsened her lupus, is different from the drug directly causing a lupus flare. The distinction matters because it changes what the risk actually is and who it applies to.
She also misidentifies Mounjaro as "the majourno," which is just a pronunciation issue, not a factual error. But it is worth noting: Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) work on overlapping but distinct receptor pathways. Having a severe reaction to both is notable and does suggest her underlying GI condition is the primary driver, not a quirk of one specific drug.
What should you actually know?
Pre-existing gastroparesis is listed as a condition requiring caution before starting GLP-1 therapy in prescribing guidelines. Davies et al. (2021, Diabetes Care) and the prescribing information for semaglutide both flag delayed gastric emptying as a relevant consideration. If you have known gastroparesis, this conversation with your prescriber is not optional, it is required before starting.
The broader lesson here is about informed prescribing, not about GLP-1 medications being broadly dangerous. For patients without gastroparesis, the GI side effect profile is generally manageable. The SUSTAIN and PIONEER trials showed that nausea and vomiting occur in roughly 15-20% of semaglutide users and typically resolve within 4-8 weeks with proper dose titration.
- Bilious vomiting for over 24 hours is not normal GLP-1 nausea. That warrants emergency evaluation.
- Lupus patients taking any new medication should have a plan for monitoring flares. Dehydration from any cause can trigger autoimmune activity.
- Tanya's decision to stop GLP-1s is reasonable given her specific medical history. It is not a universal recommendation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Tanya Livingston · TikTok creator
42.1K views on this video
Rybelsus after 3 day! gastritis and gastropresis
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about pre-existing gastroparesis?
Pre-existing gastroparesis is a clinically recognized risk factor before starting GLP-1 therapy. The 2023 AGA clinical alert specifically flagged this population as requiring careful evaluation.
What does the video say about bilious vomiting lasting over 24 hours?
Bilious vomiting lasting over 24 hours is not typical GLP-1 nausea. It is a symptom that warrants emergency care and is consistent with a gastroparesis exacerbation, not a standard side effect.
What does the video say about in the pioneer 1 trial (aroda et al., 2019, diabetes?
In the PIONEER 1 trial (Aroda et al., 2019, Diabetes Care), nausea and vomiting with oral semaglutide occurred in about 15-20% of patients, but severe hospitalization-level events were rare and not representative of typical patient experience.
What does the video say about semaglutide does not have a documented direct mechanism for triggering?
Semaglutide does not have a documented direct mechanism for triggering lupus flares. Dehydration from any cause, including severe vomiting, is a known precipitant of autoimmune disease activity.
What does the video say about tanya's experience?
Tanya's experience is a legitimate signal about prescreening failures, not evidence that GLP-1 medications are broadly dangerous for all patients.
What does the video say about patients with autoimmune conditions taking any new medication should establish?
Patients with autoimmune conditions taking any new medication should establish a monitoring plan with their prescriber before starting, including clear criteria for when to seek emergency care.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Tanya Livingston, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.